

腫瘍内科学教室

近年の主な業績

1. Machida N, Okumura T, Boku N, Kishimoto J, Nishina T, Suyama K, Ohde Y, Shinozaki K, Baba H, Tokunaga S, Kawakami H, Tsuda T, Kotaka M, Okuda H, Yasui H, Yamazaki K, Hironaka S, Muro K, Hyodo I : A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G). Cancer. 2025 ; 131(7):e35807. doi: 10.1002/cncr.35807.
2. Okano N, Pirozzi A, Abidoye O, Hoyek C, Eslinger C, Zheng-Lin B, Jamal F, Sahwan O, Sonbol MB, Uson Junior PLS, Hayashi M, Sato T, Nishioka M, Nagashima F, Bekaii-Saab T, Borad MJ, Hironaka S : Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advances. Jpn J Clin Oncol. 2025;55(7):675-690. doi: 10.1093/jjco/hyaf052.
3. Kawakami H, Kadowaki S, Makiyama A, Tsuda M, Hirata K, Sugimoto N, Machida N, Hara H, Hirano H, Esaki T, Komatsu Y, Hironaka S, Kobayashi Y, Kakimi K, Chiba Y, Boku N, Hyodo I, Muro K : Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High Advanced Gastric or Esophagogastric Junction Cancer. J Clin Oncol. 2025 ;43(19):2184-2195. doi: 10.1200/JCO-24-02463.
4. Matsuda S, Tsushima T, Kawakubo H, Hironaka S, Tsubosa Y, Sakanaka K, Oguma J, Kadowaki S, Tsunoda S, Hara H, Koyanagi K, Yamaguchi T, Harada K, Takahashi M, Minashi K, Baba E, Sasaki K, Machida R, Takeuchi H : Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314. Esophagus. 2026 ;23(1):111-119. doi: 10.1007/s10388-025-01163-2.
5. Sato T, Nagashima F, Okano N, Nishioka M, Hayashi M, Saito Y, Hisamatsu T, Hironaka S : Two cases of metastatic colorectal cancer in which epidermal growth

factor receptor gene amplification benefited from panitumumab monotherapy. *Int Cancer Conf J.* 2025 ;15(1):114-120. doi: 10.1007/s10388-025-01163-2.

6. Hirata K, Hamamoto Y, Shoji H, Hara H, Kondoh C, Yasui H, Kajiura T, Baba E, Ando T, Sugimoto N, Kawakami H, Katsuya H, Nagase M, Yamamoto Y, Yoshimura K, Ando M, Imamura CK, Yamazaki K, Hironaka S, Muro K : Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan. *EClinicalMedicine.* 2026 ; 29;92:103768. doi: 10.1016/j.eclinm.2026.103768.

7. Wakatsuki T, Yamamoto N, Ishizuka N, Hironaka S, Minashi K, Kadowaki S, Hirano H, Shoji H, Yamaguchi T, Chin K, Ogura M, Nakayama I, Osumi H, Ueki A, Kitano S, Boku N, Yamaguchi K, Takahara D : Copy Number-Based Oncogene Dominance May Suggest ERBB2 Dependence and Trastuzumab Response in HER2-Positive Gastric Cancer. *Targeted Oncology.* 2026 ;21(2):269-283. doi: 10.1007/s11523-026-01204-5.

8. Kito Y, Yamazaki K, Shoji H, Yamada T, Tsushima T, Mitani S, Shiraishi K, Yasui H, Hara H, Hirata K, Esaki T, Shinohara Y, Tsuzuki T, Kajiura S, Masuishi T, Izawa N, Baba E, Murata K, Akazawa N, Suzuki Y, Satake H, Boku N, Hyodo I, Yoshimura K, Kawakami H, Hironaka S, Muro K : Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). *Eur J Cancer.* 2026;19:238:116688. doi: 10.1016/j.ejca.2026.116688.

9. Sano Y, Kajikawa R, Mizusawa J, Ioka T, Ozaka M, Nakamura S, Ito Y, Furuse J, Kobayashi S, Fukuda H, Okusaka T, Ikeda M, Miwa H, Sasahira N, Nagashima F, Ohkawa K, Yamazaki K, Kanai M, Yamashita T, Hara K, Takayama Y, Komatsu Y, Fujimori N, Hama N, Kamata K, Hisano T, Shimizu S, Tobimatsu K, Maeda S, Ueno M : Comparison of chemoradiotherapy and gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer: an integrated analysis of two randomized phase II trials (JCOG2408A). *BMC Cancer.* 2026 ;26(1):363. doi: 10.1186/s12885-026-15699-8. PMID: 41668051; PMCID: PMC12998374.

10. Matsuoka A, Konishi Y, Boku N, Takashima A, Okusaka T, Mori K, Akechi T, Tsubata

Y, Majima Y, Uchitomi Y, Nagashima F, Fujimori M : Feasibility of a mobile application-based geriatric assessment and communication support intervention for older adults with cancer: protocol for a pilot randomised controlled trial (MAPLE2 pilot). *BMJ Open*. 2026 ;16(1):e112309. doi: 10.1136/bmjopen-2025-112309.

11. Kudo-Saito C, Imazeki H, Nagashima K, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Nagashima F, Narita Y, Yamamoto Y, Kizawa R, Muro K, Boku N. The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer. *Cancer Immunol Immunother*. 2025 ;74(12):379. doi: 10.1007/s00262-025-04239-1.
12. Kadowaki S, Otsuka T, Minashi K, Nishina S, Yabusaki H, Inagaki C, Nishina T, Yasui H, Matsuoka H, Machida N, Tsuda M, Nagashima F, Hosaka H, Matsubara J, Arai H, Ida S, Kimijima Y, Matsuda Y, Muto M, Muro K. An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study. *Gastric Cancer*. 2025 ;28(5):955-967. doi: 10.1007/s10120-025-01641-7. Epub 2025 Jul 9.
13. Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, Taniguchi H, Sunakawa Y, Yamaguchi K, Kato K, Denda T, Nishina T, Takahashi N, Satoh T, Yasui H, Satake H, Oki E, Kato T, Ohta T, Matsushashi N, Goto M, Okano N, Ohtsubo K, Yamazaki K, Yamashita R, Iida N, Yuasa M, Bando H, Yoshino T : Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors. *Nat Med*. 2025;31(1):165-175.
14. Satake T, Morizane C, Machida N, Honma Y, Okusaka T, Boku N, Kato K, Ogawa G, Sano Y, Imaoka H, Kobayashi S, Terashima T, Ikeda M, Okano N, Yamaguchi K, Sato T, Mizuno N, Kitagawa Y, Terashima M, Ueno M : Role of tumor markers before or during chemotherapy for digestive neuroendocrine carcinomas as an exploratory analysis of JCOG1213. *Sci Rep*. 2026. doi: 10.1038/s41598-026-48891-8. Online ahead of print.
15. Sano Y, Ozaka M, Aoki S, Nomura S, Mitome N, Fukuda H, Mizui T, Kamei K, Murakawa M, Eguchi H, Kawai M, Shirakawa H, Yagi S, Mizuno N, Takahashi A,

Takahashi H, Ikenaga N, Okano N, Marubashi S, Nagakawa Y, Kobayashi S, Okazaki T, Harada K, Akita H, Otsuru T, Kagawa S, Hirono S, Seo S, Arima S, Gotohda N, Fujii T, Hatano E, Unno M, Ueno M : Hepatobiliary and Pancreatic Oncology Group in Japan Clinical Oncology Group. Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients:JCOG2101C (PRESTIGE study). Jpn J Clin Oncol. 2026. doi: 10.1093/jjco/hyag055. Online ahead of print.

16. Abidoye O, Pirozzi A, Okano N, Raupach EA, Elliott N, Guzman E, Urquieta B, Rone K, Andrews K, Wu C, Sonbol MB, Ahn D, Bekaii-Saab T, Borad MJ : Bespoke circulating tumor DNA testing for diagnostic resolution, disease surveillance, and treatment monitoring in hepatopancreatobiliary malignancies: A real-world experience. JCO Precis Oncol 10(4):e2500621, 2026.
17. Terashima T, Ikeda M, Yamashita T, Okusaka T, Imaoka H, Kawaoka T, Kobayashi S, Ogasawara S, Hiraoka A, Nakano M, Okano N, Sugimoto R, Moriguchi M, Inaba Y, Shinoda S, Ueno M, Kudo M, Furuse J, Nagano H : A multicenter phase II study on atezolizumab plus bevacizumab combination therapy in patients with unresectable hepatocellular carcinoma and Child–Pugh classification B cirrhosis: CHALLENGE trial. Liver Cancer. 2026. doi:10.1159/000551476
18. Kudo-Saito C, Shoji H, Nagashima K, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Boku N : ANGPTL3 in the peripheral circulation is associated with resistance to anti-PD1 therapy in advanced gastric cancer. Cancer Res Commun. 2026 ; 6(2):350-358.
19. Pirozzi A, Hoyek C, Okano N, Sandoval LAM, Zheng-Lin B, Abidoye O, Eslinger C, Sonbol MB, Borad, MJ Bekaii-Saab T : Clinical advancements in total neoadjuvant therapy for locally advanced rectal cancer:a narrative review. AME Clinical Trials Review. 2026 ; 4(3). doi:10.21037/actr-25-58.
20. Hoyek C, Pirozzi A, Okano N, Bauernfeind JJ, Jones J, Bekaii-Saab T : Multikinase inhibitors in refractory metastatic colorectal cancer:an optimal sequence?. Clin Adv Hematol Oncol.2026; 24(1):22-28.

21. Hashimoto T, Iida N, Kadowaki S, Makiyama A, Machida N, Takahashi N, Boku S, Kudo T, Oki E, Ohtsubo K, Kawakami T, Okano N, Komatsu Y, Yuki S, Sakamoto N, Kuwata T, Yamashita R, Amisaki M, Shibuki T, Imai M, Fujisawa T, Nakamura Y, Bando H, Shitara K, Yoshino T : FGFR2-IIIc isoform detection reveals prognostic prevalence and a functional link to mesenchymal transition in gastric and gastroesophageal junction cancer. *ESMO Open*. 2025;10(11):105851.

22. Kudo-Saito C, Imazeki H, Nagashima K, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Boku N : Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer. *Discov Oncol*. 2025; 16(1):1951.

23. Kudo-Saito C, Imazeki H, Nagashima K, Shoji H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Ichikawa H, Boku N : IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer. *J Transl Med*. 2025;23(1):1125.

24. Sakamoto Y, Morizane C, Okusaka T, Mizusawa J, Hiraoka N, Shirota T, Ueno M, Kobayashi S, Ikeda M, Imaoka H, Ozaka M, Okano N, Yamaguchi H, Mizuno N, Nishina T, Katanuma A, Kojima Y, Gotoh K, Okamura K, Kawamoto Y, Sugimori K, Terashima T, Sugimoto R, Shirakawa H, Furuse J : Impact of ERCC1 on the outcomes of chemotherapy in advanced biliary tract cancer. *Sci Rep*. 2025;15(1):33862.

25. Okuyama H, Shibuki T, Okano N, Mizukami T, Yanagimoto H, Okada M, Kita E, Kobayashi N, Kobayashi S, Furukawa T, Asama H, Tsumura H, Kamata K, Umemoto K, Hamamoto Y, Suzuki Y, Horiguchi S, Naganuma A, Asagi A, Tsuji K, Takada R, Kawata K, Kojima M, Imaoka H, Terashima T, Ozaka M, Ueno M, Ikeda M : Multicenter retrospective study of efficacy of systemic therapy in patients with neuroendocrine tumor grade 3 (JOSC-2001). *Neuroendocrinology*. 2025. doi: 10.1159/000548614. Online ahead of print.

26. Kobayashi S, Nakachi K, Yamamoto K, Ueno M, Maruki Y, Ikezawa K, Terashima T, Shimizu S, Oshima K, Tsuji K, Masaki Y, Tsumura H, Shibuki T, Ozaka M, Okano N, Okamura Y, Umemoto K, Satoh T, Kojima Y, Shioji K, Nebiki H, Doi T, Naganuma A, Kataoka S, Kita E, Asama H, Tsuchiya K, Unno M, Ashida R, Matsumoto K, Ohno I,

- Itoi T, Negoro Y, Sakamoto Y, Arima S, Asagi A, Okuyama H, Komatsu Y, Kobayashi N, Nagano H, Furuse J : Combination chemotherapy for older patients with unresectable biliary tract cancer: a prospective observational study using propensity-score matched analysis (JON2104-B). *J Gastroenterol.* 2025; 60(12):1584-1595.
27. Takumoto Y, Ohba A, Terashima T, Ueno M, Ikezawa K, Okano N, Okusaka T, Morizane C, Ikeda M, Ozaka M, Narimatsu H, Akazawa M, Shiroya T, Furuse J : Electronic patient-reported outcome quality of life score in japanese patients with pancreatic cancer on second-line chemotherapy: A multicenter observational study. *Cancer Med.* 2025; 14(17):e71161.
 28. Ohba A, Ozaka M, Mizusawa J, Okusaka T, Kobayashi S, Yamashita T, Ikeda M, Yasuda I, Sugimori K, Sasahira N, Ikezawa K, Miki I, Okano N, Mizuno N, Furukawa M, Shirakawa H, Sano Y, Katayama H, Furuse J, Ueno M; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG) : Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin or S-1, irinotecan, and oxaliplatin versus nab-paclitaxel + gemcitabine in metastatic or recurrent pancreatic cancer (GENERATE, JCOG1611): A randomized, open-label, phase II/III trial. *J Clin Oncol.* 2025. doi: 10.1200/JCO.24.00936. Online ahead of print.
 29. Suzuki Y, Ikeda M, Mizusawa J, Sano Y, Morizane C, Okusaka T, Kobayashi S, Imaoka H, Terashima T, Okano N, Miwa H, Todaka A, Shimizu S, Mizuno N, Sato S, Sano K, Tobimatsu K, Katanuma A, Ozaka M, Ueno M : Comparison of clinical features by primary site in patients with biliary tract cancer who received gemcitabine-based chemotherapy: an exploratory analysis of JCOG1113. *Int J Clin Oncol.* 2025. doi: 10.1007/s10147-025-02834-x. Online ahead of print.
 30. Pirozzi A, Hoyek C, Abidoye O, Okano N, Nguyen MC, Byrne T, Aqel B, Chascsa D, Alzubaidi S, Rimassa L, Bekaii-Saab T, Borad MJ : Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report. *J Gastrointest Oncol.* 2025; 16(3):1321-1330.
 31. Hashimoto T, Iida N, Nakamura Y, Nonomura N, Morizane C, Iwata H, Okano S, Yamagami W, Yamazaki N, Kadowaki S, Ueno M, Boku S, Oki E, Komatsu Y, Yuki S,

- Makiyama A, Ogata T, Takahashi N, Okano N, Nishina T, Sakamoto N, Kuwata T, Yamashita R, Shibuki T, Imai M, Fujisawa T, Bando H, Shitara K, Yoshino T : Landscape analysis of CLDN18 expression and isoform distribution in solid tumors: Insights from MONSTAR-SCREEN-2 study. *Cancer Sci.* 2025; 116(8):2218-2231.
32. Pirozzi A, Hoyek C, Okano N, Abidoye O, Rimassa L, Sonbol MB, Uson PLS Jr, Bekaii-Saab T, Borad MJ : Pharmacologic features, clinical applications, and drug safety evaluation of futibatinib in the treatment of biliary tract cancer (BTC). *Expert Opin Drug Saf*, 2025. doi: 10.1080/14740338.2025.2495178. Online ahead of print.
 33. Imaoka H, Ikeda M, Ozaka M, Oshima K, Okano N, Shimizu S, Tsumura H, Komatsu Y, Yamashita T, Kataoka S, Nagano H, Hisano T, Sasaki M, Kobayashi S, Fukushima T, Mitsunaga S, Furukawa T, Hamauchi S, Ueno M, Furuse J : Phase 1/2 study of liposomal irinotecan plus S-1 for metastatic pancreatic cancer refractory to gemcitabine-based treatment. *Eur J Cancer.* 2025. doi: 10.1016/j.ejca.2025.115424. Online ahead of print.
 34. Okada M, Suzuki E, Morizane C, Ogawa G, Sano Y, Imaoka H, Kobayashi S, Ikeda M, Okano N, Miwa H, Todaka A, Shimizu S, Mizuno N, Satoi S, Sano K, Tobimatsu K, Katanuma A, Masutomi K, Okusaka T, Ozaka M, Ueno M, members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG) : Impact of clinically diagnosed liver cirrhosis in patients with intrahepatic cholangiocarcinoma treated with systemic chemotherapy: a subgroup analysis of JCOG1113. *Jpn J Clin Oncol.* 2025; 55(6):594-602.
 35. Fukushi K, Imaoka H, Ikeda M, Mizusawa J, Morizane C, Okusaka T, Kobayashi S, Sasahira N, Shimizu S, Yamazaki K, Okano N, Miwa H, Hara K, Satoi S, Sano K, Sakai K, Sugimoto R, Nakamura K, Terashima T, Ozaka M, Ueno M, JCOG Hepatobiliary and Pancreatic Oncology Group : Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113. *Jpn J Clin Oncol.* 2025;55(4):355-361.
 36. Imaoka H, Ikeda M, Kobayashi S, Ohba A, Ueno M, Suzuki Y, Tsumura H, Kimura N, Kawaguchi S, Kawamoto Y, Nakachi K, Tsuji K, Kobayashi N, Ashida R, Okano N, Umemoto K, Murohisa G, Hosokawa A, Asagi A, Nebiki H, Suzuki R, Terashima T,

- Shibata R, Kawata K, Doi T, Ohyama H, Kitano Y, Shioji K, Okuyama H, Naganuma A, Negoro Y, Sakamoto Y, Shimizu S, Morizane C, Ueno M, Furuse J, Nagano H; Japan Oncology Network in Hepatobiliary and Pancreas. Efficacy of liposomal irinotecan + 5-FU/LV vs. S-1 in gemcitabine-refractory metastatic pancreatic cancer: a real-world study using inverse probability of treatment weighting. *J Gastroenterol* 60(3):356-367, 2025.
37. Shoji H, Kudo-Saito C, Nagashima N, Imazeki H, Tsugaru K, Takahashi N, Kawakami T, Amanuma Y, Wakatsuki T, Okano N, Narita Y, Yamamoto Y, Kizawa R, Muro K, Aoki K, Boku N. Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study). *J Immunother Cancer* 12(11):e010174.
 38. Okano N, Pirozzi A, O'Donnell C, Hayashi M, Serrano Uson Junior PL, Hoyek C, Abidoye O, Eslinger C, Zheng-Lin B, Elliott NM, Raupach EA, Zhou Y, Petit J, Ahn D, Sonbol MB, Wu C, Nishioka M, Sato T, Teixeira MF, Sforzin I, Babiker HM, Majeed U, Tran NH, Rimassa L, Nagashima F, Hironaka S, Bekaii-Saab T, Borad, MJ : Time toxicity in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin with or without durvalumab. *JCO Oncology Advances*.3(1). 2026. DOI:10.1200/oa-25-00126
 39. Okano N, Sakamaki K, Mie T, Watanabe K, Kobayashi S, Todaka A, Suzuki Y, Kitamura H, Tanaka K, Nakagawa K, Kamei K, Umemoto K, Azemoto N, Kawamoto Y, Yanagimoto H, Tsuji K, Imaoka H, Terashima T, Morizane C, Ikeda M, Ozaka M, Ueno M, Furuse J; Japan Observational Study Committee of Hepatobiliary and Pancreatic Oncology (JOSC-HBP) : Outcomes of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in patients with early recurrent pancreatic cancer after adjuvant S-1 treatment: A propensity score-matched analysis. *Pancreatology*. 2025 ; 25(6):950-958.
 40. Okano N, Pirozzi A, Abidoye O, Hoyek C, Eslinger C, Zheng-Lin B, Jamal F, Sahwan O, Sonbol MB, Uson PLS Jr, Hayashi M, Sato T, Nishioka M, Nagashima F, Bekaii-Saab T, Borad MJ, Hironaka S. Systemic therapy for pretreated advanced biliary tract cancer: past developments and recent advances. *Jpn J Clin Oncol*. 2025 ; 55(7):675-690.